$1,318.00
This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and an epidemiological overview.
Norovirus is an RNA virus of the Caliciviridae family, and a human enteric pathogen that causes inflammation of the intestines and/or stomach, known as acute gastroenteritis. Human noroviruses are the principal cause of pandemic gastroenteritis in people of all age groups.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
9 EPIDEMIOLOGY
9 Norovirus outbreaks
9 Challenges for vaccine development
11 PIPELINE DRUGS
15 PROBABILITY OF SUCCESS
16 LICENSING AND ASSET ACQUISITION DEALS
16 Takeda Takes Alliance Route For Norovirus Vaccine
17 CLINICAL TRIAL LANDSCAPE
18 Sponsors by status
19 Sponsors by phase
20 BIBLIOGRAPHY
21 APPENDIX
LIST OF FIGURES
11 Figure 1: Overview of pipeline drugs for norovirus in the US
11 Figure 2: Pipeline drugs for norovirus, by company
12 Figure 3: Pipeline drugs for norovirus, by drug type
12 Figure 4: Pipeline drugs for norovirus, by classification
15 Figure 5: Probability of success in the antiviral pipeline
17 Figure 6: Clinical trials in norovirus
17 Figure 7: Top 10 drugs for clinical trials in norovirus
18 Figure 8: Top 10 companies for clinical trials in norovirus
18 Figure 9: Trial locations in norovirus
19 Figure 10: Norovirus trials status
19 Figure 11: Norovirus trials sponsors, by phase
LIST OF TABLES
13 Table 1: Pipeline drugs for norovirus in the US
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!